Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''

Br J Cancer. 2017 Apr 11;116(8):e11. doi: 10.1038/bjc.2017.61. Epub 2017 Mar 14.

Authors

Takeo Fujii^{1

2}, Naoto T Ueno¹

Affiliations

¹ Department of Breast Medical Oncology, Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
² Department of Biostatistics, The University of Texas Health Science Center at Houston School of Public Health, 1200 Pressler Street, Houston, TX 77030, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms*
Humans
Neoadjuvant Therapy*
Nomograms
Receptor, ErbB-2

Substances

Receptor, ErbB-2